新華醫療(600587.SH):神思醫療擬進行存續分立
格隆匯6月5日丨新華醫療(600587.SH)公佈,公司控股子公司山東神思醫療設備有限公司(“神思醫療”)擬進行存續分立,分立後,神思醫療繼續存在,同時分立出一家新公司(“新設公司”),新設公司的股權架構與神思醫療一致,為新華醫療持有55%股權,自然人鄒倩麗持有45%股權。此次存續分立事項不會對公司的正常經營、未來財務狀況和經營成果產生重大影響。
神思醫療目前的生產經營場地主要在山東省濟南市的奧盛大廈和孫村工業園區兩個地方,距離較遠,為提高管理效率,降低經營成本,公司董事會同意神思醫療進行存續分立。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.